Company Description
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders.
The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022.
Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jun 7, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 84 |
| CEO | Abraham Ceesay |
Contact Details
Address: 99 High Street, Suite 2100 Boston, Massachusetts 02110 United States | |
| Phone | 857 321 8020 |
| Website | rapportrx.com |
Stock Details
| Ticker Symbol | RAPP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 2012593 |
| CUSIP Number | 75383L102 |
| ISIN Number | US75383L1026 |
| Employer ID | 88-0724208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Abraham N. Ceesay M.B.A. | Chief Executive Officer, President, Treasurer and Director |
| Dr. Steven M. Paul M.D. | Founder and Independent Chairman |
| Dr. Troy A. Ignelzi | Chief Financial Officer |
| Cheryl Gault | Chief Operating Officer |
| Karina Chmielewski | Chief Information Officer and Head of Operations |
| Julie DiCarlo | Head of Communications and Investor Relations |
| Kathleen A. Wilkinson | Chief People Officer |
| Swamy Yeleswaram Ph.D. | Chief Development Officer |
| Dr. Arnold R. Gammaitoni Pharm.D. | Senior Vice President of Medical Affairs |
| Gregg Keaney Ph.D. | Senior Vice President of CMC and Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 144 | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 21, 2026 | SCHEDULE 13G | Filing |
| Jan 15, 2026 | 144 | Filing |
| Jan 7, 2026 | 8-K | Current Report |
| Jan 7, 2026 | 424B5 | Filing |